Logi Analytics announced that eClinical Insights has embedded its Logi Info into its core applications
Logi Analytics, an analytics company, announced that eClinical Insights, a provider of cloud-based clinical trial intelligence software, has embedded its Logi Info into its core applications, delivering comprehensive Business Intelligence (BI) capabilities, simplified reporting and visualizations for researchers. eClinical Insights offers Software-as-a-Service (SaaS) products that enable customers to take a data-driven approach to the management of clinical trials. The company's offerings include data operations management software that provides visibility into clinical trials and a clinical BI application that delivers interactive data visualizations of key performance metrics, risk indicators and data trends. eClinical Insights chose the BI tool based on its ease of use and straightforward interface.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.